Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARWIN3: Filgotinib Long-term Extension in Rheumatoid Arthritis
NCT02065700Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2014
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of filgotinib in rheumatoid arthritis (RA), sponsored by Galapagos NV. Started Feb 2014; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02065700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065700.